Functionality against models of multiple myeloma was demonstrated recently in pre-clinical in vitro and in vivo studies, both as monotherapy and in combination with daratumumab (anti-CD38) elotuzumab (anti-SLAM7) or anti-CD19. Here, CD38 is linked to plasma cell myeloma.